H2020HORIZON
Ttopstart BV
- Country
- NLNetherlands
- Defence projects
- 0
- Projects, all programmes
- 14
- As coordinator
- 1
- EU contribution (CORDIS)
- EUR 1,459,635
- Active
- 2015 to 2022
Projects
14 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| canSERVProviding cutting edge cancer research services across Europe | HORIZON | 2022 | Participant | EUR 160,000 |
| ONCOVALUEImplementing value-based oncology care at European cancer hospitals: An AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time | HORIZON | 2022 | Third party | Not stated |
| OPTIMAOptimal treatment for patients with solid tumours in Europe through Artificial intelligence | H2020 | 2021 | Participant | EUR 326,218 |
| AMELIEAnchored Muscle cELls for IncontinencE | H2020 | 2020 | Participant | EUR 180,750 |
| TICARDIOThrombo-inflammation in cardiovascular disease | H2020 | 2019 | Partner | EUR 0 |
| ELBAEuropean Liquid Biopsies Academy - Towards widespread clinical application of blood- based diagnostic tools | H2020 | 2018 | Partner | EUR 0 |
| PIONEERProstate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope | H2020 | 2018 | Participant | EUR 237,500 |
| ENTWINEThe European Training Network on Informal Care | H2020 | 2018 | Partner | EUR 0 |
| UTILEThe EU-HEALTH INNOVATION MARKETPLACE, the valorization platform for (FP7 Health and H2020 SC1) research results | H2020 | 2017 | Coordinator | EUR 87,230 |
| PREDICTA new era in personalised medicine: Radiomics as decision support tool for diagnostics and theragnostics in oncology | H2020 | 2017 | Partner | EUR 0 |
| IMMUNISAA Next Generation Immunotherapy for Human Papilloma Virus induced Cervical Cancer | H2020 | 2017 | Participant | EUR 183,875 |
| PRECIOUSScaling-up biodegradable nanomedicines for multimodal for multimodal precision cancer immunotherapy | H2020 | 2016 | Participant | EUR 159,062 |
| REGAINREgeneration of inner ear hair cells with GAmma-secretase INhibitors to regain hearing in patients with sensorineural hearing loss | H2020 | 2015 | Participant | EUR 125,000 |
| InCeMResearch Training Network on Integrated Component Cycling in Epithelial Cell Motility | H2020 | 2015 | Partner | EUR 0 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.